Effects of α-GalCer on subcutaneous tumor growth and tumor angiogenesis.
Wild-type B6 mice were intradermally inoculated with B16-BL6 (1 × 105) cells and intraperitoneally administered α-GalCer (2 μg/200 μL) or vehicle (200 μL) from day 0 and then every 4 days for 28 days. (A) Tumor size was measured every 4 days after tumor inoculation. Data are represented as the mean ± SD of 5 mice in each group. Similar results were obtained in 2 independent experiments. *P < .05 compared with vehicle. (B) The tumor-inoculated sites in vehicle- or α-GalCer–treated mice at day 10. (C) Tumor-inoculated sites were isolated from vehicle- or α-GalCer–treated mice when the tumor size reached the indicated volumes and tumor-supplying vessels were counted. The mean tumor sizes of vehicle- and α-GalCer–treated groups were not different within any one range described. (At 100 to 200 mm3, vehicle 153 ± 24, α-GalCer 161 ± 22. At 300 to 400 mm3, vehicle 365 ± 25, α-GalCer 358 ± 34. At greater than 500 mm3, vehicle 622 ± 56, α-GalCer 608 ± 70.) Data are represented as the mean ± SD of 5 mice in each group. Similar results were obtained in 2 independent experiments. *P < .01.
